Isaac Kobrin, one of TOLREMO’s co-founders and Chairman of the Board, is an internationally trained internist with 23 years of experience in the pharmaceutical industry. As Global Group Leader of the Cardiovascular Development Group at Roche he was responsible for the worldwide clinical development of key compounds (from Phase 1 to marketing approval). In 1999, Isaac joined Actelion Pharmaceuticals as Senior Vice President, Head of Clinical Development, and member of Actelion's Executive Committee. He later became Chief Medical Officer and chairman of the Strategic and Portfolio Board of Actelion. 3 drugs were approved under his leadership and he was also directly involved in numerous regulatory interactions with the US-FDA and the European EMEA/CHMP.
PROF. DR. WILHELM KREK
Wilhelm Krek is one of TOLREMO’s co-founders and has been Full Professor of Cell Biology at ETH Zurich since 2003. He is a world-leader in cancer cell signaling and has worked at the Friedrich Miescher Institute for Biomedical Research (FMI), Basel, and at the Dana Farber Cancer Institute/Harvard Medical School in Boston. He also co-founded the ETH Spin-off ProteoMedix AG, the Institute of Molecular Health Sciences and the NEXUS Personalized Health Technologies Platform at ETH Zurich. For his work on cell signaling and disease mechanisms, he received several honors including the Robert Wenner Prize, the Friedrich Miescher Medal, the International Steiner Cancer Research Award and the Swiss Bridge Award. He is elected member of EMBO and the American Association for Cancer Research.
PROF. DR. KARL-HEINZ ALTMANN
Karl-Heinz Altmann co-founded TOLREMO and is Full Professor of Pharmaceutical Sciences and current Head of Department of Chemistry and Applied Biosciences at ETH Zurich. Before (re-)joining academia in 2003, he gained 13 years of experience as chemist and group leader at Ciba-Geigy and Novartis Pharma. In 2000, he was appointed Novartis Senior Chemistry Expert at Oncology Research of Novartis Pharma. Later he became acting Global Head of Chemistry of the Novartis Institutes for BioMedical Research (NIBR). At ETH Zurich his research group is centered on the chemical synthesis of pharmaceutically relevant natural products and their biological evaluation, with a particular focus on leads for anticancer and antituberculosis drug discovery. For his scientific achievements, Karl-Heinz was awarded the Paul Ehrlich Prize of the Société de Chimie Thérapeutique, France, in 2014.
DR. STEFANIE FLÜCKIGER-MANGUAL, CEO
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and expert in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientist who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.
EMMANUEL SAVIOZ, CFO
Emmanuel Savioz, Chief Financial Officer and co-founder, started his career in finance in New York as an investment banker in mergers and acquisitions handling large international transactions in consumer goods and healthcare. He then obtained an MBA from the Haas School of Business, University of California at Berkeley. Over the past 7 years, he has arranged CHF 70 million of equity financing. Emmanuel is a serial entrepreneur and has also co-founded the life science company Phi Pharma SA, the technology company Preciflex SA, the luxury watch company HYT SA.